Nasdaq
$24.50▲ 0.12%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.86BShares out 1.200M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 9.15After-hours26.09.16 05:158-KKey event#●●●#●●●#●●●
Parabilis Medicines, Inc.
Parabilis Medicines is updating its guidance to present updated clinical data from the ongoing Phase 1/2 study of zolucatetide in desmoid tumor patients. The presentation is scheduled for October 24, 2026, at the ESMO Congress in Madrid.…more
$24.50+0.12%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.2After-hours26.09.03 05:058-KKey event
Parabilis Medicines, Inc.
Parabilis Medicines' Chief Medical Officer, Dr. Fawzi Benzaghou, has mutually agreed with the company to depart effective September 30, 2026. In connection with his departure, Dr. Benzaghou will receive severance benefits as stipulated in his employment agreement.…more
$24.50+0.12%vs prev closeView filingShare - 8.25After-hours26.08.26 07:144Ownership
Parabilis Medicines, Inc.
Insider Craig Tendler of Parabilis Medicines reported a change in beneficial ownership of securities effective August 22, 2026. This is a standard regulatory filing disclosing insider transactions that shareholders should review.…more
$24.50+0.12%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 22h agoClosed26.10.24 21:45#●●●#●●●
Parabilis Medicines Reports Positive Phase 1/2 Data for Zolucatetide in Desmoid Tumors…more
Parabilis Medicines announced compelling efficacy and favorable safety results for zolucatetide in patients with desmoid tumors from its Phase 1/2 trial. The company plans to initiate a registrational Phase 3 trial in the first half of 2027 based on these findings.…more
$24.50+0.12%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 6d agoPre-market26.10.19 20:00
●●●●●●●● ●●●●● ●●●●●●
Parabilis Medicines will present updated Phase 1/2 clinical data for zolucatetide in patients with desmoid tumors at the ESMO Congress 2026. The findings from the dose optimization arm are intended to guide the design and regimen for a planned Phase 3 registrational trial.…more
$24.50+0.12%vs prev close - 10.14Pre-market26.10.14 20:00
●●●●●●●● ●●●●● ●●●●●●
Parabilis Medicines has initiated a dose-ranging clinical cohort for its lead candidate, zolucatetide, in patients with familial adenomatous polyposis (FAP). This study aims to define the optimal dose and schedule for future registrational trials, building on early clinical evidence of polyp reduction.…more
$24.50+0.12%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report